What is PharmaIN?
PharmaIN Corporation is dedicated to pioneering first- and best-in-class subcutaneous therapies for challenging conditions such as liver disease and cancer. Leveraging advanced peptide engineering, the company aims to create novel, self-injectable treatments that significantly improve the quality of life for patients suffering from advanced liver cirrhosis. Their focus on patient independence and effective health management is a cornerstone of their development strategy. The company is actively pursuing strategic partnerships to accelerate the development of its therapeutic candidates.
How much funding has PharmaIN raised?
PharmaIN has raised a total of $1.6M across 2 funding rounds:
Private Equity
$1.5M
Debt
$150K
Private Equity (2014): $1.5M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Key Investors in PharmaIN
PPP
Public-Private Partnership
What's next for PharmaIN?
With a substantial enterprise-level funding context and a recent major strategic investment, PharmaIN is poised for significant growth and development. The company's focus on advancing PHIN-214 through clinical trials, coupled with its innovative peptide engineering platform, suggests a strategic direction towards expanding its therapeutic offerings and potentially entering new market segments. Future endeavors will likely involve further clinical validation, regulatory submissions, and the establishment of key collaborations to bring their novel treatments to patients worldwide. The company's commitment to self-injectable therapies indicates a strong emphasis on patient-centric solutions and market differentiation.
See full PharmaIN company page
